[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BioMarin Pharmaceutical, Inc. (BMRN)
BioMarin Pharmaceutical (BMRN) sees increased social volume with positive sentiment around FDA approvals and technical momentum, despite concerns over acquisition impacts on earnings.
About BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases.
BioMarin Pharmaceutical, Inc. uses the ticker $BMRN for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- BioMarin Pharmaceutical, Inc. (BMRN) Galaxy Score™ is up XXXXX% from the previous week.
- BioMarin Pharmaceutical, Inc. (BMRN) sentiment is up XXXXX% from the previous week.
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The stock is trading near its 1-year low, influenced by broader market downturn and acquisition cost concerns. However, positive sentiment from technical analysis, potential FDA approvals, and social posts highlighting the stock as undervalued may provide some support.
24-Hour: -XXXX% 7-Day: -XXX% 30-Day: -XXXX%
1-Year High: $XXXXX on 2025-03-27
1-Year Low: $XXXXX on 2025-11-07
AltRank: XXXXX
AltRank 24-Hour Time-Series Raw Data
BioMarin Pharmaceutical, Inc. (BMRN) is currently AltRank #1,156 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXXXX +248
X Month: XXXXX +472
X Months: XXXXX +267
X Year: XXXXX +406
1-Year High: XXXXX on 2025-04-05
1-Year Low: X on 2025-02-16
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +8
X Month: XX +5
X Months: XX -X
X Year: XX -XX
1-Year High: XX on 2025-07-15
1-Year Low: XX on 2025-06-18
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXXX -XX%
X Month: XXXXXXX -XX%
X Months: XXXXXXXXX -XX%
X Year: XXXXXXXXX +101%
1-Year High: XXXXXXX on 2025-02-19
1-Year Low: XXX on 2025-03-23
Engagements by network (24h): Reddit: XXX X: XXX YouTube: XX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXX +38%
X Year: XXXXX +35%
1-Year High: XXX on 2025-06-17
1-Year Low: XX on 2025-01-27
Mentions by network (24h): Reddit: XXX X: XXX YouTube: X
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning BioMarin Pharmaceutical, Inc. (BMRN) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX
X Week: XX -XX%
X Month: XXX -XXXX%
X Months: XXXXX +92%
X Year: XXXXX +68%
1-Year High: XXX on 2025-06-30
1-Year Low: XX on 2025-12-07
The most influential creators that mention BioMarin Pharmaceutical, Inc. in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @bpra93 | X | XXXXXX | XX | XXX |
| @AsAboveSoBelow322 | X | XXXXX | X | XX |
| @seedytx19 | X | XXXXX | X | XX |
| @john_steel70462 | X | XXX | X | XX |
| @BuyTheUgly | X | XX | X | XX |
| @bryan_plat47867 | X | XXX | X | XX |
| @Biobeats99 | X | XXX | X | XX |
| @ParadiseTraderr | X | XXX | X | XX |
| @BioPharmCatalyst | X | XX | X | XX |
| @Iam__Mouni | XX | XXX | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XXX% +43%
X Month: XXX% +38%
X Months: XXX% +23%
X Year: XXX% +20%
1-Year High: XXX% on 2025-11-10
1-Year Low: XX% on 2025-01-06
Most Supportive Themes:
- FDA Approvals and Partnerships: (45%) Posts highlight positive sentiment regarding potential FDA approvals and strategic partnerships, indicating strong market interest and confidence in the company's pipeline.
- Technical Analysis and Momentum: (25%) Discussions focus on technical analysis, identifying key support and resistance levels, and noting accelerating intraday momentum, suggesting positive trading signals.
- Financial Performance and Growth: (15%) Mentions of financial updates, including revenue growth and the impact of acquisitions, suggest a positive outlook for the company's financial performance and future prospects.
Most Critical Themes:
- 52-Week Lows and Market Concerns: (10%) Some posts mention BMRN hitting 52-week lows, reflecting broader market concerns and potential negative impacts on the stock price.
- Acquisition Impact on Earnings: (5%) The acquisition of Inozyme Pharma is expected to negatively impact earnings per share in Q3 2025, which could be a concern for investors.
Social Dominance: XXXXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
X Week: XXXXXX% -XXXXXX%
X Month: XXXXX% -XXXXX%
X Months: XXXXX% -XXXXXX%
X Year: XXXXX% -XXXXX%
1-Year High: XXXXX% on 2025-01-08
1-Year Low: XXXXXX% on 2025-09-21
Market Dominance: XXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-03-11
1-Year Low: XXXXX% on 2025-12-12
Market Cap: $XXXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXX -$0.57%
X Month: $XXXXXXXXXXXXXX -$4.30%
X Months: $XXXXXXXXXXXXXX -$5.70%
X Year: $XXXXXXXXXXXXXX -$19%
1-Year High: $XXXXXXXXXXXXXX on 2025-03-27
1-Year Low: $XXXXXXXXXXXXX on 2025-11-07
Top BioMarin Pharmaceutical, Inc. Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Wall Streets TOP XX PICKS for 2026 Among $10$30B market-cap names ranked by upside: 🔟 $NTNX +49% X $HUBS +51% X $AVAV +58% X $NBIS +61% X $CRCL +63% X $BMRN +67% X $TTD +68% X $FIG +69% X $SMMT +81% X $IREN +86% Which one are you backing for 2026"
X Link @gainify_io 2025-12-12T12:03Z 11.5K followers, 1863 engagements
"Bernstein🏁 $BBIO at an Outperform-$94 and said 'Ample Upside Even if Attruby Hits Choppy Seas. Initiate at Outperform $XX PT' $ALNY $PFE AZN BAYRY BMRN ASND Bernstein additionally said in its BridgeBio initiation report: We believe expectations for ATTR-CM drug Attruby are reasonable near/mid-term and arguably too high long term while we see upside to consensus numbers for infigratinib and encaleret. We are in line for BBP-418. Key proprietary analyses in this initiation: ATTR-CM doc survey infigratinib doc feedback infigratinib Ph3 trial analysis. Our survey of N=30 ATTR docs was less"
X Link @Quantumup1 2025-12-11T11:13Z 3928 followers, 1641 engagements
"So damn bullish here $SMMT $ZGNX $IONS $PASG $ETNB $OTLK $RYTM $RGNX $NGM $UTHR $IMVT $REGN $ADAP $NBIX $PDSB $IGMS $BMRN $ALEC $ALLO $SUPN $TRVI $BIIB $ARVN $ZURA $NVAX $JAZZ $IDYA $INCY $EXEL $CMRX $ALKS $ABCL $DAWN $ICPT"
X Link @BuyTheUgly 2025-12-09T20:12Z XX followers, XXX engagements
"This is HUGE $BMRN $ALEC $ALLO $SUPN $TRVI $BIIB $ARVN $ZURA $NVAX $JAZZ $SBTX $IDYA $INCY $EXEL $CMRX $ALKS $NAMS $ABCL $DAWN $ICPT $IRTC $ACHL $PTGX $KRYS $TGTX $PRVB $ENta $RXRX $AMRN $IRWD $URGN $RPTX $SAGE $ARWR $VACC $TWST $FOLD $MRTX"
X Link @BuyTheUgly 2025-12-09T20:09Z XX followers, XXX engagements